TP53 and breast carcinoma: In contrast to colon cancer cells, in breast cancer cells, compound 24b upregulated only p21 in the p53-wildtype MCF-7 cells, while T47D cells (p53L194F) treated with compound 24b showed no p21 changes but activation of PARP1, albeit compound 24b inhibited the mortalin-p53 interaction in both cell lines [101].